Previous Article | Next Article 
Journal of Virology, December 1998, p. 10138-10147, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Host Cell-Virus Cross Talk: Phosphorylation of a
Hepatitis B Virus Envelope Protein Mediates Intracellular
Signaling
Kirsten
Rothmann,1
Martina
Schnölzer,2
Gerald
Radziwill,3
Eberhard
Hildt,4
Karin
Moelling,3 and
Heinz
Schaller1,*
Zentrum für Molekulare Biologie
Heidelberg1 and
DKFZ,2 D-69124 Heidelberg, and
Institut für Experimentelle Chirurgie, Klinikum
Rechts der Isar, D-81675 Munich,4
Germany, and
Institut für Medizinische Virologie,
CH-8028 Zurich, Switzerland3
Received 26 May 1998/Accepted 20 August 1998
 |
ABSTRACT |
Phosphorylation of cytosolic pre-S domains of the duck hepatitis B
virus (DHBV) large envelope protein (L) was identified as a regulatory
modification involved in intracellular signaling. By using biochemical
and mass spectrometric analyses of phosphopeptides obtained from
metabolically radiolabeled L protein, a single phosphorylation site was
identified at serine 118 as part of a PX(S/T)P motif, which is strongly
preferred by ERK-type mitogen-activated protein kinases (MAP kinases).
ERK2 specifically phosphorylated L at serine 118 in vitro, and L
phosphorylation was inhibited by a coexpressed MAP kinase-specific
phosphatase. Furthermore, L phosphorylation and ERK activation were
shown to be induced in parallel by various stimuli. Functional analysis
with transfected cells showed that DHBV L possesses the ability to
activate gene expression in trans and, by using mutations eliminating
(S
A) or mimicking (S
D) serine phosphorylation, that this function
correlates with L phosphorylation. These mutations had, however, no
major effects on virus production in cell culture and in vivo,
indicating that L phosphorylation and transactivation are not essential
for hepadnavirus replication and morphogenesis. Together, these data
suggest a role of the L protein in intracellular host-virus cross talk
by varying the levels of pre-S phosphorylation in response to the state
of the cell.
 |
INTRODUCTION |
Hepatitis B viruses (HBVs), or
hepadnaviruses, are small enveloped DNA viruses which replicate in the
livers of their respective hosts via reverse transcription of an RNA
pregenome (18, 37). Although causing liver damage by the
host immune response, hepadnavirus infections are per se noncytopathic,
indicating that these viruses have optimized a strategy aimed at
establishing inapparent, productive, long-term persistent infections.
This is particularly well illustrated in case of the avian viruses,
such as duck HBV (DHBV), which normally circumvent host defense
mechanisms by vertical transmission. With the mammalian viruses, the
nonpathogenic carrier state is probably best illustrated by
HBV-transgenic mice, which produce virus titers comparable to those of
chronic HBV patients without any indication of liver disease
(21).
These and other indications of a well-balanced replication strategy
which avoids major pathogenic effects suggest the existence of an
intimate cross talk between virus and host. Evidence for such
mechanisms has become apparent in a number of recent reports demonstrating a variation in hepadnavirus gene expression as a result
of changes in the intracellular state of the host hepatocyte in
response to extracellular signals. Perhaps most notable is the
cytokine-mediated down regulation of HBV expression in HBV-transgenic mice upon infection with various animal viruses (8). Another example is the rapid termination of virus production which is observed
upon plating of hepatocytes from HBV-transgenic mice, with a similar
effect also being seen in freshly plated DHBV-infected primary duck
hepatocytes (PDHs) (41). Furthermore, establishment of DHBV
infection has been shown to be sensitive to drugs that raise the
intracellular cyclic AMP level (23). Finally, it has long
been known that DHBV covalently closed circular DNA is vastly overamplified in aging PDHs (56), suggesting the existence
of regulatory mechanisms compensating for the reduced viral gene expression.
The mechanisms underlying these responses are presently only poorly
understood, and equally little is known about the potential role of
hepadnavirus gene products in these processes. Circumstantial experimental evidence suggests that hepadnaviruses encode proteins with
regulatory functions which help to establish and maintain infection
through direct or indirect modulation of cellular targets. The
mammalian viruses, such as human HBV or woodchuck HBV, express low
levels of the nonstructural X protein, which has been shown to activate
gene expression from a great variety of cellular and viral promoters
(46). Consistent with a regulatory function, the HBx gene
product is not required for virus production from transfected HBV DNA
genomes (60); it appears to be essential, however, for the
establishment of infection in vivo (61). No homolog to the
HBx gene, or any other open reading frame for nonstructural proteins,
is present in the genomes of the avian hepadnaviruses, which
nevertheless respond to changes in the state of the cell. This raises
the possibility that structural proteins may be used for regulatory
functions, at least in the avian hepadnaviruses.
Several observations suggest that this may indeed be the case for
products of the pre-S/S gene, which encodes the viral envelope proteins. The largest of these proteins (the large envelope protein [L
protein]) carries, in addition to the S domain, which constitutes the
small envelope protein (S protein), an N-terminal extension, the pre-S
domain, which has important functions at different stages of the viral
life cycle; it mediates the receptor interaction during cellular virus
uptake (30, 57) and, in an alternate topology with a
cytosolic pre-S domain, presumably interacts, in a matrix-like
function, with the nucleocapsid during virus formation (6,
18). The cytosolic pre-S domain has also been implicated in
regulating the level of intracellular genome replication. Mutational
analysis with DHBV-infected cells had indicated that mature
nucleocapsids were not exported in the absence of L protein but instead
were redirected into the nuclear reimport pathway, enhancing the level
of nuclear DNA templates (33, 54). In these studies, not all
the effects of certain pre-S mutations could be explained by this
simple stoichiometric feedback model. For example, N-terminal
truncations of the L protein caused both elevated levels of covalently
closed circular DNA and enhanced virus production (54),
suggesting the existence of an additional, nonstoichiometric regulatory
role of cytosolic DHBV pre-S domains. That the DHBV L protein may carry
a regulatory function is also suggested by the observation that the
protein is phosphorylated to variable extents in cytosolic pre-S
domains (19), as is often observed in regulatory proteins.
Finally, despite its multiple functions, the pre-S region (and the
underlying spacer region in the polymerase gene) shows by far the
highest sequence variation between the various members of the
hepadnavirus family (53); it could therefore represent a
genome segment especially apt to evolve accessory regulatory functions.
While potential regulatory pre-S functions cannot be analyzed in
experimental HBV infections, a transactivating activity with characteristics similar to the HBx gene product has been identified by
transfection analysis of HBV pre-S variants. Initially detected in
C-terminally truncated middle envelope proteins with inverted topologies (25, 26), this activity has more recently also been observed in the HBV L protein (the full-length pre-S/S gene product) and correlated with a cytosolic pre-S disposition
(24). However, evidence for an involvement of this
transactivation function in virus-controlled regulatory processes is lacking.
Based on the above-described observations, and in view of the
limitations of the mammalian systems, we decided to study a possible
regulatory role of pre-S phosphorylation in the DHBV animal model,
which allows functional studies in cell culture and in vivo. After
mapping of the L phosphorylation site and subsequent functional
analysis with respect to virus replication, we have obtained evidence
for a possible interactive role of L phosphorylation in cellular
regulatory circuits. We report a DHBV L transactivating activity and
its correlation with L phosphorylation by an ERK-type mitogen-activated
protein kinase (MAP kinase) in response to extracellular stimuli, and
we propose a model where L phosphorylation modulates viral replication
in response to the host cell status.
 |
MATERIALS AND METHODS |
Nomenclature.
By assigning the designations p36 to the
phosphorylated form of DHBV L (molecular mass, 36.2 kDa) and p35 to the
nonphosphorylated form, we follow Grgacic and Anderson (19)
and deviate from earlier publications using p37/p35 or p37/p36,
respectively (15, 42, 49).
Plasmids and mutations.
Plasmids for expression of DHBV L in
tissue culture were based on a construct, pMT-DL, which contains
nucleotides (nt) 727 to 2815 of the DHBV subtype 16 (DHBV16) genome
(34), encoding the pre-S/S gene downstream of the human
metallothionine IIA promoter (55). L transcripts
from this promoter are predicted to be very similar to the pre-S
transcripts produced in vivo, which start at nt 732 and terminate at
around nt 2800 (39). To facilitate introduction of mutations
at the serine 118 codon (nt 1152 to 1154), two unique restriction sites
(not affecting the pre-S open reading frame and making only
serine-to-threonine exchanges in the polymerase) were introduced by
point mutations, T1157A (BstXI) and A1124T
(BspEI). Synthetic oligonucleotide duplexes between these
sites were then used to change codon 118 from TCC to GCC (coding for
alanine) in plasmid pMD-L-S118A and from TCC to GAC (coding for
aspartate) in plasmid pMD-L-S118D. pMD-L
116 expresses L protein with
a deletion of amino acids 11 to 126 (55).
Plasmid pSG5-CL100myc for the expression of myc-tagged CL100 (MAP
kinase phosphatase [2]) was kindly provided by S. M. Keyse.
For production of DHBV particles from transfected LMH cells, we used
pMT-D3, a plasmid containing a 10% overlength DHBV3 genome (53) driven by the metallothionine IIA promoter
to produce genomic DHBV transcripts, in analogy to the cytomegalovirus
promoter-driven plasmid pCD0 (39). Codon 118 in the L gene
(TCT) was changed to GCT (for alanine) or to GAT (aspartate) by
site-directed mutagenesis. In the polymerase open reading frame, these
mutations change isoleucine 328 to serine or arginine, respectively. As
isoleucine 328 is in the variable spacer region of the polymerase gene,
these mutations are not expected to affect the functionality of the
enzyme (44).
32P metabolic labeling of DHBV-infected PDHs and
preparation of L protein.
Primary hepatocytes from DHBV3-infected
ducks were prepared and maintained as described previously (45,
56). At day 7 to 14 postplating, 1.2 × 107
cells in a 10-cm-diameter plate were phosphate starved for 1 h in
phosphate-free Dulbecco's modified Eagle's medium (ICN) and incubated
with 4 to 6 mCi of 32Pi in 3.5 ml of the same
medium. Incubation was for 5 h at 37°C with gentle rocking.
Cells were washed three times with phosphate-buffered saline, scraped
from the plate in 1 ml of TNE (10 mM Tris, 100 mM NaCl, 1 mM EDTA, pH
8.0), and broken by three cycles of freeze-thawing. Crude membrane
fractions were prepared as described previously (19) by
centrifugation for 2 min at 10,000 rpm and 5 min at 6,500 rpm
(Eppendorf Microfuge), resuspension of the membrane pellet in TNE-1%
Nonidet P-40 (NP-40), and centrifugation again for 2 min at 10,000 rpm
and 5 min at 6,500 rpm to remove the nuclei. L protein was
immunoprecipitated from the resulting supernatant with the monoclonal
antibody (MAb) 4F8 (recognizing pre-S amino acids 100 to 105)
covalently coupled to 20 µl of protein A-Sepharose beads (CL-4B;
Pharmacia) with dimethylpimelimidate. After repeated washing with
TNE-1% NP-40, the beads were boiled in 20 µl of protein sample
buffer (200 mM Tris-HCl [pH 8.8], 10% sucrose, 3% sodium dodecyl
sulfate [SDS], 5 mM EDTA, 2% 2-mercaptoethanol, 0.1% bromophenol blue), and the extract was applied to a 10% gel. By this method, 6,000 to 20,000 cpm of 32P-labeled L protein (detected as a p36
band) was obtained. For preparing large amounts of unlabeled L protein,
the procedure was upscaled by using freshly prepared hepatocytes from a
perfused DHBV-infected liver (a 30-g liver yielding approximately
10 g of hepatocytes). Crude membrane fractions (30 to 40 ml from
10 g of hepatocytes) were cleared by centrifugation for 20 min at 17,000 × g. Samples were preabsorbed with protein
A-Sepharose beads for 2 h to reduce background binding and then
immunoprecipitated for 3 h at 4°C with approximately 1 mg of MAb
4F8 covalently coupled to 200 µl of protein A-Sepharose beads. After
repeated washing, L protein was recovered from the beads by boiling in
100 µl of protein sample buffer. The beads were reextracted twice
with 100 µl of water, and pooled extracts were concentrated to 50 µl by evaporation in a Speed-Vac and loaded onto an SDS-10%
polyacrylamide gel. The starting material for analysis of AspN peptides
(see Fig. 1C and Table 1) was p36 protein isolated from 30 g of
DHBV-infected hepatocytes supplemented with 5,000 cpm of
32P-labeled p36.
In-gel protease digestion and extraction of peptides from gel
slices.
For in-gel protease digestion, a Coomassie blue-stained L
protein band (approximately 8 by 2 mm) was excised from an SDS-10% polyacrylamide gel and cut into small cubes (approximately 2 by 2 mm).
Gel pieces were destained four times with 100 µl of
acetonitrile-water (1:1) and suspended in 50 µl of acetonitrile,
resulting in shrinking of the gel cubes. The supernatant was discarded,
and 50 µl of 100 mM NH4HCO3 was added. After
15 min of swelling, the gel pieces were again shrunk in 50 µl of
acetonitrile and dried briefly in a Speed-Vac. The dried pieces were
then submerged in 100 µl of protease digestion buffer containing 12.5 µg of trypsin or AspN (Boehringer Mannheim, sequencing grade) per ml;
digestion buffer for trypsin contained 50 mM
NH4HCO3, 5 mM CaCl2, and 10%
acetonitrile, and digestion buffer for AspN contained 50 mM phosphate
buffer (pH 8.0) and 10% acetonitrile. After soaking of the gel cubes by incubation for 30 min on ice, surplus digestion buffer was replaced
by buffer without protease so that the gel pieces were just covered,
and samples were then incubated at 37°C overnight for trypsin
digestion or for 6 h for AspN digestion. The supernatants were
saved and pooled with the peptide-containing extracts described below.
Peptides were extracted from the gel pieces twice with 50 µl of 25 mM
NH4HCO3 and then three times with 50 µl of
5% formic acid (or two times with 70% trifluoracetic acid-water and
two times with trifluoracetic acid-acetonitrile [1:1]), with a
50-µl of acetonitrile shrinking after every step. All extraction
steps were carried out with gentle shaking at 30 to 37°C. Volumes
were kept as small as possible to reduce the final volume of the
peptide pool. All extracts (including the acetonitrile from shrinking steps) were pooled and dried down in a Speed-Vac. For high-pressure liquid chromatography (HPLC) analysis, tryptic peptides (extracted with
trifluoracetic acid) were resuspended in 0.1% trifluoracetic acid. For
analysis on a protein gel, AspN peptides were resuspended in 20 µl of
sample buffer (50 mM Tris-HCl [pH 6.8], 12% [wt/vol] glycerol, 4%
SDS, 2% 2-mercaptoethanol, 0.01% bromophenol blue). The described
elution procedure generally resulted in recovery of about 80% of
32P-labeled peptides.
For high resolution of AspN peptides, separation was performed on a
16.5% Tris-Tricine gel (
48). Peptide bands (approximately
8 by 2 mm) were excised, cut into very small cubes (1 by 1 mm),
washed
for 15 min in 40 µl of 50% methanol-10% acetic acid and
then for
10 min in 40 µl of 10% methanol-7.5% acetic acid, and
shrunk with
20 µl of acetonitrile. Washes were discarded, and
peptides were
extracted by incubating the gel pieces for 1 h each
in 30 µl of
100 mM NH
4HCO
3, 30 µl of 25 mM
NH
4HCO
3, and 30 µl
of 25 mM
NH
4HCO
3-acetonitrile (1:1), with shrinking
with 20 µl
of acetonitrile after every step. Extractions were carried
out
with gentle shaking at 37°C in 200-µl tubes with a tiny hole in
the bottom so that liquid could be removed into a collection tube
by a
short spin. Pooled extracts were concentrated to 2 to 5 µl
in a
Speed-Vac and directly analyzed by mass
spectrometry.
Mass spectrometry.
Matrix-assisted laser
desorption-ionization (MALDI) mass spectra were recorded with
-cyano-4-hydroxycinnamic acid as the matrix on a Reflex II
time-of-flight instrument (Bruker-Franzen, Bremen, Germany) equipped
with a SCOUT multiprobe inlet and a 337-nm nitrogen laser. Tryptic
peptides were analyzed in the positive-ion reflector mode with an ion
acceleration voltage of 28.5 kV and a reflector voltage of 30 kV. AspN
peptides were recorded in the positive-ion reflector mode with delayed
extraction. The ion acceleration voltage was set to 28.5 kV, the
reflector voltage was 30 kV, and the first extraction plate was set to
18.5 kV. Mass spectra were obtained by averaging 50 to 100 individual
laser shots. Calibration of the spectra was performed externally by a
two-point linear fit with angiotensin I and insulin.
Phosphoamino acid analysis.
The procedures used here are
basically as described by Boyle et al. (5). For total acid
hydrolysis, tryptic 32P-labeled peptides (containing 1,500 cpm) were incubated in 300 µl of 6 M HCl with 0.1% phenol for 4 h at 110°C under nitrogen. The sample was repeatedly frozen,
lyophilized, and resuspended in water to result in a clear pellet. Two
microliters of pH 3.5 running buffer (pyridine-glacial acetic
acid-water, 1:10:189 [vol/vol/vol]), 2 µl of unlabeled
phosphoaminoacid standard
(phosphoserine-phosphothreonine-phosphotyrosine, each 10 µg/µl),
and 1 µl of xylene cyanol (1 mg/ml) were added. The sample was
applied to a Merck 20- by 20-cm thin-layer cellulose plate
(premoistened with pH 3.5 running buffer) and separated by
two-dimensional electrophoresis in a flat-bed electrophoresis unit.
Electrophoresis in the first dimension was performed with the pH 3.5 buffer for 1.5 h at 850 V (13 W). The plate was dried, moistened
with pH 1.9 buffer (88% formic acid-glacial acetic acid-water, 25:78:897 [vol/vol/vol]), and electrophoresis in the second dimension was performed with pH 1.9 buffer for 2.5 h at 1,000 V (15 W). After drying, standard phosphoamino acids were detected by ninhydrin staining (0.2% in ethanol; Sigma), and labeled phosphoamino acids were
detected by exposure on a PhosphorImager.
Transient expression and detection of L protein.
LMH cells
(11) or COS7 cells were seeded at a density of 5 × 106 to 6 × 106 cells per 10-cm-diameter
dish and transfected 24 h later with 10 µg of pMT-DL by the
calcium phosphate method. Cells were lysed at 2 to 4 days
posttransfection by incubation for 10 min at 4°C in 1 ml of TNE-1%
NP-40. Cell debris was removed from the lysate by centrifugation at
13,000 rpm for 10 min, and L protein was immunoprecipitated from the
supernatant with polyclonal antiserum (D084) directed against the
N-terminal two-thirds of DHBV pre-S. Typically, immunoprecipitates from
one or half of a 10-cm-diameter dish (COS7 or LMH cells, respectively)
were analyzed for L protein by Western blotting with MAb 4F8
(recognizing amino acids 100 to 105 in pre-S). In cotransfection
experiments, 10 µg of pMT-DL and 15 µg of pSG5-CL100myc were used
per 10-cm-diameter dish. CL100myc was immunoprecipitated and detected
in Western blots with a myc MAb (9E10; Invitrogen). For
-phosphatase
digestion of L protein, the immunoprecipitated L protein was digested
directly on beads with 400 U of
-phosphatase (New England Biolabs)
for 30 min at 30°C in a final volume of 50 µl of reaction buffer
containing 0.5% NP-40.
Hepatocyte lysates and cell stimulation.
To determine the
phosphorylation state of L protein in lysates of DHBV-infected liver,
small pieces of liver tissue (or pelleted PDHs) were weighed and Dounce
homogenized in a small volume of protein sample buffer, and volumes
were adjusted with protein sample buffer to 25 mg of tissue per ml.
Plated PDHs were lysed by applying 400 µl of protein sample buffer
per six-well plate (2 × 106 cells), resulting in
lysates with approximately 25 mg of protein per ml. In general, for the
gels shown in Fig. 5, 250 µg of protein was applied per lane.
Comparable protein contents of the samples were confirmed on a
Coomassie blue-stained gel in parallel with the Western blot for L
protein (MAb 4F8). Antisera for detection of total ERK1/2 and active
ERK1/2 (anti-ACTIVE-MAPK) in hepatocyte lysates were obtained from
Santa Cruz Biotechnology and Promega, respectively.
PDHs from DHBV-infected ducks were subjected to different stimuli
starting 4 to 6 h postplating: incubation at 20°C for 14
to
16 h or at 46°C for 15 min, UV irradiation at 30 to 80 J/m
2 for 45 min, or treatment with 100 nM
12-
O-tetradecanoylphorbol-13-acetate
(TPA) for 15 min or
with 10 µg of anisomycin per ml for 30
min.
In vitro kinase assays with L protein from subviral
particles.
DHBV particles were purified from sera of wild-type
DHBV- or S118A-DHBV-infected ducklings essentially as described
previously (30). Briefly, 30 ml of serum, containing ca.
5 × 109 viral particles/ml and ca. 5 × 1012 subviral particles/ml, was layered on a sucrose
gradient and sedimented onto a cushion of 70% sucrose in 1×
phosphate-buffered saline-1 mM EDTA. Subviral particle-containing
fractions were pooled, concentrated by polyethylene glycol
precipitation (see below), and further purified by centrifugation into
a second sucrose step gradient (70 to 20% sucrose in 5% steps, 1 ml
each) at 218,000 × g for 4 h at 20°C. Subviral
particle-containing fractions were directly used for in vitro kinase
assays: 5 µl (containing 100 to 200 ng of L protein) was incubated
for 20 min at 30°C with 100 ng of activated mouse glutathione
S-transferase (GST)-tagged ERK2 (GST-p42MAPK; UBI) in 20 µl of kinase reaction buffer (50 mM Tris-HCl [pH 7.5], 10 mM
MgCl2, 0.1 mM EDTA, 0.5% NP-40, 2 mM dithiothreitol, and
10 mM
-glycerophosphate) containing 5 µCi of
[
-32P]ATP. L protein was immunoprecipitated with
anti-pre-S antiserum D084 and subjected to SDS-10% polyacrylamide gel
electrophoresis (SDS-10% PAGE). 32P-labeled proteins were
detected in dried gels with a PhosphorImager.
CAT assays.
HepG2, LMH, or 293 cells were seeded at a
density of 3 × 106 to 5 × 106 cells
per 6-cm-diameter dish and transfected 24 h later with 2 µg of
the chloramphenicol acetyltransferase (CAT) reporter construct p3xAP1-CAT (27) and either 6 to 8 µg of different L
expression plasmids or a control plasmid without L insert by the
Lipofectin method. At 2 days posttransfection, cells were lysed in 250 mM Tris-HCl, pH 8.0. After centrifugation to remove nuclei and cell debris, the cytosolic fraction was used to determine CAT activities as
previously described (25).
Infection of PDHs with virus from cloned DHBV DNA.
Wild-type
DHBV and S118A- and S118D-DHBV were harvested from the media at days 5 and 8 following transfection of LMH cells with 10 µg of
pMT-D3-derived plasmid per 10-cm-diameter dish. To determine the yield
of enveloped virions, an aliquot of the sample was centrifuged into a
CsCl step gradient (1.4, 1.3, and 1.2 g/ml and 20% sucrose), and DHBV
DNA in each fraction was quantified relative to a standard by dot blot
hybridization as previously described (39). If necessary,
virus was concentrated to titers of up to 3 × 109
DNA-containing virus particles per ml by precipitation with
polyethylene glycol (final concentration, 6.5%) in 350 mM NaCl.
Concentrated virus stocks were kept in phosphate-buffered saline
containing 10% glycerol at
20°C.
PDHs (2 × 10
6 cells in one six-well plate, 3 days
postplating) were infected overnight with 10
8 virus
particles. Infection efficiency and virus replication were
monitored by
determining the DHBV DNA by DNA dot blotting of the
culture
supernatants from days 1 to 5, 5 to 9, 9 to 13. Cell lysates
(lysis
buffer was 0.1 M Tris-HCl [pH 8.8], 1% SDS, 10 mM EDTA,
and 0.1%
2-mercaptoethanol) were digested with proteinase K and
extracted with
phenol-chloroform to increase the sensitivity of
viral DNA detection by
dot blot
hybridization.
 |
RESULTS |
DHBV L protein is phosphorylated at serine 118.
The
nonphosphorylated and the phosphorylated forms of the L protein (p35
and p36, respectively) were efficiently separated by preparative
SDS-PAGE (Fig. 1A, lane 1) of L
immunoabsorbed from crude membrane preparations of DHBV3-infected
PDHs. In a parallel preparation from metabolically
32P-labeled cells (Fig. 1A,
lanes 2 and 3), p36 was the only phospholabeled L protein species, as
reported previously (19). For further analysis, the bands
containing either p36 or p35 were excised from the gel, and proteins
were digested with endoproteinase AspN or with trypsin as described in
Materials and Methods. The resulting mixture of peptide fragments was
either used for phosphoamino acid analysis or further resolved for
identification of individual phosphopeptides by mass spectrometry.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 1.
DHBV L contains a single major phosphopeptide with
serine phosphorylation. (A) Preparative purification of phosphorylated
DHBV L protein. Membrane-associated L protein from DHBV-infected
hepatocytes was enriched by immunoadsorption and purified by SDS-10%
PAGE (lane 1) (starting material, approximately 5 g of
hepatocytes). In parallel, L proteins from 32P-labeled
hepatocytes were separated. The single 32P-labeled band
(lane 3) coincided with p36, as visualized by Coomassie blue staining
(lane 2). (B) Phosphoamino acid analysis of 32P-labeled
p36. After acid hydrolysis, the constituent amino acids were separated
by two-dimensional thin-layer chromatography. The positions of
phosphoamino acid standards detected by ninhydrin staining are
indicated by solid lines on the autoradiogram. (C) Separation of
32P-labeled p36 AspN peptides. After SDS-PAGE on a 16.5%
Tris-Tricine gel (48), radiolabeled peptides were detected
by autoradiography. *, minor AspN peptide.
|
|
Phosphoamino acid analysis of
32P-labeled p36, performed
with the tryptic digest eluted from the gel, showed that the radiolabel
was linked exclusively to serine residues, with no radiolabel
being
detected at the positions of phosphothreonine or phosphotyrosine
(Fig.
1B). Separation of
32P-labeled AspN peptides on a 16.5%
Tris-Tricine gel (Fig.
1C)
revealed that 90% of the radioactivity
migrated as a single band
with an apparent molecular mass of 3.5 kDa, a
result demonstrating
the presence of a single major phosphopeptide in
DHBV L. After
elution from the gel, a mass of 4,221.8 Da was determined
for
this peptide. This value corresponds closely to the mass calculated
for a singly phosphorylated AspN cleavage product, comprising
amino
acid residues 93 to 127 in the pre-S domain of DHBV L (4,220.6
Da)
(Table
1 and Fig.
2), whereas values for any other
phosphoserine-containing
peptide, possibly arising from complete or
partial AspN cleavage
of DHBV L, were calculated to be at least 372 Da
lower or 92 Da
higher. In DHBV3, the subtype used in this experiment,
the peptide
from amino acid 93 to 127 contains only a single serine
residue
at position 118 (Fig.
2); we therefore concluded that this
serine
residue was the site for DHBV L phosphorylation. This
interpretation
was further supported by the good correlation of the
mass values
determined and calculated for the corresponding AspN
peptide from
the unphosphorylated L protein species, p35, which were
4,140.0
and 4,140.6 Da, respectively (data not shown). Moreover, a
second,
minor
32P-labeled AspN phosphopeptide, representing
the remaining 10%
of the radioactivity and migrating at approximately
4.5 kDa (marked
by an asterisk in Fig.
1C), was found to possess a mass
of 4,282.2
Da, which is only 60.4 Da higher than the one determined for
the
major AspN phosphopeptide (Table
1). As outlined above, this
value
does not correspond to any other singly or doubly phosphorylated
peptide resulting from AspN cleavage of L protein. Furthermore,
the
relative fraction of this minor peptide, by
32P content,
varied severalfold between experiments (not shown);
it therefore most
likely represents the product of a modification,
apparently caused by
unspecified variations of the experimental
conditions during isolation,
adding 60 Da to the major phosphopeptide.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 2.
DHBV L protein is phosphorylated at serine 118. Phosphopeptides matching the mass values obtained by mass spectrometry
(see Table 1 and text) are shown in the context of the DHBV3 L protein
amino acid sequence. As phosphoserine was the only phosphoamino acid
detected in p36 (Fig. 1B), serine 118 must be the DHBV L
phosphorylation site.
|
|
Tryptic peptides from the p36 protein were characterized by
reverse-phase HPLC of
32P-labeled digestion products.
Peptides from three major peak fractions
which contained similar
amounts of radiolabel (40, 34, and 26%,
respectively) were analyzed
further. Mass spectrometry revealed
that the first two peptides, which
were present in two directly
adjacent fractions, contained two closely
related peptides with
mass values determined to be 2,583.6 and 2,569.5 Da (peptide 1
and peptide 2, respectively [Table
1]). Further mass
spectrometric
analysis in the reflectron mode (
3), showed a
metastable fragmentation
of phosphoric acid, indicating that both
peptides contained only
a single phosphate group (data not shown). The
mass determined
for tryptic peptide 2 corresponds well to the mass of
2,566.7
Da predicted for the tryptic cleavage product encompassing
phosphorylated
serine 118 (amino acids 103 to 123) (Table
1 and Fig.
2), whereas
mass values for other phosphoserine-containing tryptic
pre-S peptides
are predicted to be at least 100 Da higher or 1,000 Da
lower.
The apparent mass increase of 14 Da in peptide 1 is therefore
best explained by the addition of a single oxygen atom (16 Da)
to
peptide 2, possibly as the result of proline or tryptophan
hydroxylation (
31). Mass spectrometric analysis of the third
HPLC fraction, containing 26% of the radiolabel, did not give
conclusive results. Conceivably, this peptide may have also contained
a
derivative of the tryptic phosphopeptide from amino acid 103
to 123, possibly carrying the modification adding 60 Da that was
observed with
the phosphopeptides from the AspN digest. Thus,
the majority of the
phosphorylated tryptic peptides recovered
from metabolically labeled
p36 was found to correspond to phosphopeptides
containing serine 118, a
result confirming the more complete mapping
of the phosphorylation site
by analysis of the AspN peptides presented
above.
Confirmation of DHBV L phosphorylation at serine 118 by mutational
analysis.
As phosphorylation results in reduced migration of DHBV
L in SDS-PAGE, mutations changing serine 118 are expected to influence the electrophoretic mobility of the L protein. To test this prediction, serine 118 was replaced either by alanine, thereby eliminating phosphorylation at this site, or by aspartate, which is commonly used
to functionally mimic protein phosphorylation. Wild-type or mutant
DHBV16 L proteins were expressed in transfected LMH cells (a chicken
hepatoma cell line [11]) and analyzed by
immunoblotting for changes in migration during SDS-PAGE. As expected,
replacement by alanine (S118A) resulted in the complete disappearance
of the slower-migrating p36 species (Fig.
3, compare lanes 2 and 3), as was
observed after incubation of phosphorylated wild-type protein with
-phosphatase (lane 1). Replacement of serine 118 by aspartate (S118D) resulted in a single L protein species migrating between p35
and p36 (Fig. 3, lane 4), an observation demonstrating that the
negative charge introduced with the aspartate residue at position 118 was sufficient to reduce the electrophoretic mobility of DHBV L,
although not to the same degree as the doubly charged phosphate. Taken
together, these results demonstrate that the reduced mobility of the
p36 L protein species in SDS-polyacrylamide gels correlates with its
phosphorylation at serine 118; they thus prove the conclusions drawn
from the biochemical mapping of the phosphorylation site. Moreover, as
biochemical mapping was performed with L protein from DHBV3 and
mutational analysis was performed with DHBV16, these data demonstrate
that pre-S phosphorylation at serine 118 is independent of the DHBV
subtype.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 3.
Mutational analysis confirming that phosphorylation at
serine 118 causes the electrophoretic mobility shift leading to the p36
L species. LMH cells were transfected with DHBV 16 L expression
constructs coding for wild-type (lanes 1 and 2) or mutated (S118A for
removing the phosphorylation site [lane 3] and S118D for mimicking
phosphoserine [lane 4]) L proteins. L proteins in cell lysates at day
8 posttransfection were immunoprecipitated, separated on an SDS-10%
polyacrylamide gel, and detected by anti-pre-S Western blotting.
|
|
DHBV L protein is phosphorylated by an ERK-type MAP kinase.
The extracellular signal-regulated protein kinases ERK1 and ERK2
(isoforms) are members of the MAP kinase family (7). In the
DHBV L protein sequence, serine 118 is part of a PXSP sequence (Fig.
2), a motif that is recognized by ERKs in preference to other SP sites
(12, 51). There are no basic residues in its vicinity, which
argues against the possibility that phosphorylation may alternatively
involve protein kinase C, protein kinase A, or a member of the
cyclin-dependent kinase family, the other group of SP- or TP-targeted
kinases (28, 51).
In order to test whether ERK was indeed participating in L
phosphorylation, L protein from detergent-disrupted subviral particles
was used as a substrate in an in vitro phosphorylation assay with
GST-tagged ERK2. As shown in Fig.
4A,
ERK2 was indeed capable
of phosphorylating DHBV L, resulting in a
strongly radiolabeled
p36 band detected by SDS-PAGE (lane 1).
Phosphorylation was specific
for serine 118, as mutant L protein
carrying the S118A mutation
was not converted into p36 (Fig.
4A, lane
2), even though comparable
amounts of L protein had been present in the
reaction mixture
(as demonstrated by Coomassie blue staining [not
shown]). Weak
radioactive signals were seen slightly above the
position of p35
with the wild-type and the mutant proteins. These were
probably
due to minor L phosphorylation of (S/T)P sites outside serine
118, which do not cause a major mobility shift in SDS-PAGE
(
20).
In summary, these data demonstrate that highly
purified ERK2 can
strongly and specifically phosphorylate the DHBV L
protein at
serine 118, the site shown to be the target of
phosphorylation
in vivo.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 4.
DHBV L is phosphorylated by an ERK-type MAP kinase. (A)
In vitro kinase assay. Wild-type (wt) or S118A-DHBV particles were
incubated with GST-tagged ERK2 and [ 32P]ATP in a
reaction buffer which contained 0.5% NP-40 to disrupt the particles. L
proteins were immunoprecipitated and separated by electrophoresis on an
SDS-10% polyacrylamide gel, and radiolabeled proteins were detected
by autoradiography. (B) Inhibition of phosphorylation at serine 118 by
CL100, a phosphatase which specifically inactivates MAP kinases. COS7
cells were transfected with an L expression plasmid (pMT-DL) and a
myc-tagged CL100 expression construct (pSG5-CL100myc) as indicated.
Cells were lysed at day 2 posttransfection, and L proteins were
immunoprecipitated and detected by Western blotting after separation on
an SDS-10% polyacrylamide gel (lanes 1 and 2). To check for this
presence, CL100myc protein was also immunoprecipitated from the lysate
of cells cotransfected with L and CL100 and detected on the same
Western blot (lane 3) (double stained with anti-pre-S and anti-myc).
*, signals from mouse immunoglobulin G used for precipitating
CL100myc.
|
|
To confirm an involvement of a MAP kinase in DHBV L phosphorylation, we
investigated whether CL100, a phosphatase specifically
inactivating MAP
kinases by returning them to the dephosphorylated
inactive state
(reviewed in reference
29), had an inhibitory
effect
on L phosphorylation in transfected COS7 cells. As shown
in Fig.
4B, L
protein phosphorylation (lane 1) was indeed reduced
strongly upon
cotransfection of a construct expression CL100 (lane
2), confirming
that an activated MAP kinase was most likely responsible
for L
phosphorylation. Direct dephosphorylation of L by CL100
is improbable
because of the high specificity of this phosphatase
for MAP kinases
(
2). Taken together, the results from kinase
assays
performed in vitro and with transfected cells strongly
suggest that an
ERK-type MAP kinase is responsible for L protein
phosphorylation at
serine
118.
L protein phosphorylation induced by extracellular stimuli
correlates with activation of ERK 1/2.
In our initial experiments,
major variations in the extent of L protein phosphorylation were
observed between DHBV-infected duck livers and PDH cultures that had
been maintained for different time periods. In a more systematic
follow-up, liver samples and cultured hepatocytes from the same
DHBV-infected donor duck were analyzed before and during the course of
liver perfusion, as well as over extended time periods after plating.
Changes in L protein phosphorylation, indicated by the p35/p36 ratio,
were monitored by anti-pre-S Western blots (Fig.
5A, lanes 2 to 11), with L protein from
serum DHBV particles (known to be only marginally phosphorylated) being
included as a reference (Fig. 5A, lane 1). As shown in Fig. 5A (lane
2), the phosphorylated form of the L protein (p36) was barely
detectable in the liver. It increased progressively, however, as the
liver cells were liberated by perfusion and suspended in the
maintenance medium, as is demonstrated in Fig. 5A (lane 3) by L protein
obtained from suspended cells taken 30 min after the start of
perfusion. Samples taken at earlier time points during collagenase
treatment showed intermediate p36 levels which increased with time. In
PDH cell cultures, p36/p35 ratios initially stayed constant and
decreased slowly after day 6 (Fig. 5A, lanes 7 to 9). It should be
noted that the increase in L phosphorylation in response to perfusion
and plating varied between PDH cultures from different test animals
(compare Fig. 5A, lanes 2 and 4, to Fig. 5B, upper panel, lanes 1 and
2), as did the decrease of p36 levels after day 6 (data not shown).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 5.
L phosphorylation induced by extracellular stimuli
correlates with ERK activation. (A) Time course of preparation and cell
culture of hepatocytes from a DHBV-infected duck. Total proteins from
hepatocyte lysates (lanes 2 to 11) were separated by SDS-10% PAGE,
and L protein was detected by Western blotting. In lane 6, 1.3 times
more lysate was applied to compensate for a reduction of DHBV proteins
reproducibly observed at around day 6 postplating. Cold treatment
(lanes 10 and 11) was performed for 12 h starting at 6 h
postplating. Two microliters of a DHBV-positive serum, containing
approximately 5 × 1010 subviral particles, was
applied as a reference (lane 1). susp. hep., suspended hepatocytes. (B)
Effects of various stimuli on PDHs from a second DHBV-infected duck.
Hepatocyte lysates were separated by SDS-10% PAGE, and L protein
(upper panel) and active ERK1/2 (lower panel) were detected by Western
blotting.
|
|
The levels of phosphorylated L protein could be enhanced further,
particularly in freshly plated PDHs, in response to various
extracellular stimuli. Strong increases were observed after exposure
to
low temperature (overnight at 20°C [Fig.
5A, lane 11, and B
upper
panel, lane 3]), UV irradiation (Fig.
5B, upper panel, lane
7), or a
mitogenic phorbolester (TPA) (Fig.
5B, upper panel, lane
4). A
stimulatory response was also obtained with anisomycin,
an inhibitor of
translation (Fig.
5B, upper panel, lane 6), while
no change in p36
levels was observed after heat shock at 46°C
(lane 5) (the avian body
temperature is 42°C). Except for the
effect of anisomycin, which is
known to stimulate stress-activated
MAP kinases and not ERKs, these
observations are again in keeping
with an involvement in L
phosphorylation of mitogen-activated
ERK-type MAP kinases. In contrast,
there was little correlation
with the activation profile of
stress-activated MAP kinases, such
as JNK and p38, which are typically
stimulated by heat shock (
32).
UV irradiation, which
enhanced L protein phosphorylation, is known
to stimulate primarily
JNKs but also ERKs (
43); the strong activation
in response
to cold treatment observed here has, to our knowledge,
not yet been
noticed in any other
system.
Taken together, the data presented so far suggested that L
phosphorylation correlated with ERK activation. To test whether
this
correlation was also observed during the changes in L phosphorylation
in freshly plated hepatocytes, Western blots of PDH lysates from
the
above-described experiments were probed with an antiserum
recognizing
only the active form of ERK1/2 (Fig.
5B, lower panel)
and, as a
control, with an antiserum recognizing both inactive
and active ERK1/2
(not shown). In this analysis, the amounts of
activated ERK varied in
close correlation with induction of L
phosphorylation (Fig.
5B, compare
upper and lower panels), while
the total ERK protein content was found
to be comparable in all
samples. These observations again support the
hypothesis that
an ERK-type MAP kinase is responsible for
phosphorylation of the
DHBV L
protein.
Phosphorylation at serine 118 mediates activation of gene
expression in trans.
Pre-S transactivation has been
extensively studied in HBV, and a segment essentially corresponding to
the pre-S2 subdomain has been identified in transient-transfection
experiments as the minimal transactivating unit (24, 25). To
test whether the L protein of DHBV carried a similar transactivator
activity, HepG2 cells, a human hepatoma cell line, were transfected
with plasmids expressing different L protein variants (Fig.
6A) or a control plasmid without L
insert, together with a CAT reporter construct used previously in
transactivation assays with the HBV L protein (p3xAP1-CAT
[24]). At 2 days posttransfection, cells were lysed and the cytosolic fraction was used to determine CAT activities. Wild-type DHBV L protein was found to activate expression of the reporter gene up to sevenfold (Fig. 6A, lane 1) relative to a DHBV L
deletion mutant lacking two-thirds of the pre-S domain (L
116) (Fig.
6A, lane 4), indicating that an intact pre-S domain is a prerequisite
for a transactivation function of DHBV L. In other CAT assays with
transfected LMH cells, up to 10-fold transactivation was observed
relative to the vector plasmid without DHBV insert (not shown). To
examine whether L transactivation was linked to a cytosolic orientation
of the pre-S domain, we included a construct which results in
cotranslational translocation of the pre-S domain into the lumen of the
endoplasmic reticulum through an N-terminally fused signal sequence
(sigL1 [55]). As expected, the lack of cytosolic pre-S
domains resulted in complete loss of transactivating activity (data not
shown).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 6.
Serine 118 is essential for transactivating function of
the DHBV L protein. (A) CAT assays. HepG2 cells were cotransfected with
expression plasmids for DHBV16 L proteins and a 3xAP 1-driven CAT
reporter construct. CAT activity was measured in cell lysates prepared
at 2 days posttransfection. Bars represent mean values with standard
deviations from four transfections. Fold inductions were calculated
relative to the value for the pre-S deletion mutant L 116. (B)
Comparable expression of the different L proteins was confirmed by
Western blotting of immunoprecipitated L proteins. L 116, 22 kDa;
*, glycosylated L 116 protein (55).
|
|
We next examined whether the L transactivation function was related to
phosphorylation at serine 118 by testing L protein
mutations abolishing
and functionally mimicking phosphorylation
(S118A and S118D,
respectively) in the transactivation assay.
Transactivation was
completely lost with the S118A mutant (Fig.
6A, lane 2), whereas the
transactivation potential of L was conserved
after replacement of
serine 118 with aspartate (Fig.
6A, lane
3).
To exclude the possibility that the changes observed were related to
potential differences in L protein expression and/or
protein stability,
the L proteins were visualized by Western blotting
and were found to be
expressed at comparable levels (Fig.
6B).
The transactivating activity
of L thus appears to depend on the
presence of a negative charge at
position 118 (provided by either
phosphoserine or the substituting
aspartate). The low level of
phospho-L in the wild-type protein (Fig.
6B, lane 1, p36) does
not contradict this interpretation if we assume
that a lower transactivation
potential of L-S118D was compensated for
by the higher number
of transactivating protein molecules. This
hypothesis is supported
by observations with other phosphoproteins (for
example, MAP kinase
kinase-1 [
1]) indicating that
comparable substitutions may
only partially mimic the activating effect
of a phosphorylated
amino acid. Furthermore, the amounts of
transactivating proteins
and the levels of their transactivating
activities do not necessarily
correlate directly (
14).
Nevertheless, although not quantitatively
interpretable, the apparent
equivalence of transactivation by
wild-type DHBV L and L-S118D is an
important complement to the
loss of transactivation function by the
alanine
substitution.
Mutations in DHBV L that eliminate or mimic phosphorylation at
serine 118 do not significantly influence viral replication.
To
test whether mutational changes at serine 118 which affect L protein
phosphorylation and transactivation corresponded to a phenotype in
virus replication, we introduced the S118A and the S118D mutations into
a cloned replication-competent, overlength DHBV genome. These
constructs were then transfected into LMH cells to produce DHBV
particles, which were subsequently assayed for their competence to
initiate the complete viral replication cycle in PDHs or in infected
ducklings. In these experiments, transfected LMH cells produced virions
from S118A-DHBV or from S118D-DHBV with yields comparable to those
obtained with wild-type DHBV, thus demonstrating that phosphorylation
was not of central importance for virus formation and maturation or any
other late step in the viral life cycle. In DHBV-infected PDHs, again
no differences in infection competence were observed between wild-type
virus and either of the mutant viruses as judged from the amounts of DHBV DNA secreted into the tissue culture medium (Fig.
7) or by virus cell-to-cell spread as
visualized by immunofluorescence staining at day 4 or 9 post infection
(data not shown). Replication kinetics were also tested by quantifying
total intracellular virus DNA in PDH lysates (between days 1 and 17 post infection), and again no differences exceeding a factor of 2 were
observed (data not shown). We therefore conclude that mutations
affecting phosphorylation at serine 118 have no significant effects on
viral infection and replication in the cell culture system.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 7.
Mutations at serine 118 do not significantly influence
viral replication. Primary duck hepatocytes were infected with
wild-type (wt) DHBV or variant viruses (carrying L-S118A or L-S118D)
produced from LMH cells. The viral DNA contents in tissue culture
supernatants collected at the indicated time intervals were determined
by dot blot analysis relative to a DHBV DNA standard by using a
PhosphorImager. Each point is the average of values from two wells.
|
|
To test the situation in vivo, ducklings were infected 1 day after
hatching with wild-type or mutant virus produced from LMH
cells. As
judged from serum DHBV DNA titers determined before
and at several time
points after infection, all animals developed
titers of between 2 × 10
9 and 5 × 10
10 DNA-containing virus
particles per ml at 1 to 2 weeks after infection.
Serum viremia varied
substantially between individual test animals,
but these differences in
virus titer and kinetics were not reproducibly
related to the genotype
of the infecting virus. These results,
like those from the infection
studies with PDHs presented above,
thus indicate that phosphorylation
at serine 118 is not of critical
importance for viral
replication.
 |
DISCUSSION |
In this study we show that a hepadnavirus envelope protein with
functions in virus morphogenesis and cellular entry can serve an
additional regulatory function through phosphorylation-mediated cross
talk influencing gene expression. The results reported here for the
DHBV L protein support and extend earlier observations with HBV
envelope proteins indicating that cytosolically exposed pre-S domains
possessed the potential to activate gene expression from cellular
promoter elements in trans (24, 25); this further suggests that this unconventional property is evolutionarily conserved despite the fact that there is only fragmentary amino acid sequence identity between the pre-S domains of avian and mammalian
hepadnaviruses (53).
Other known examples of transactivation activities of structural viral
proteins are the influenza virus hemagglutinin (40) and the
large hepatitis delta antigen (58). In contrast to DHBV L,
however, there is no evidence that these transactivating activities can
be modulated in response to extracellular stimuli. Our studies on DHBV
L further indicate that this modulation is mediated by phosphorylation
at a unique serine residue: L protein with the mutation S118A
completely lost transactivation activity, whereas the protein with the
S118D mutation transactivated an AP1 promoter-linked indicator gene
comparably to the (partly phosphorylated) wild-type protein (Fig. 6).
These results strongly suggest that a negative charge in position 118 (provided by either phosphoserine or the substituting aspartate) is
essential for the transactivating activity of DHBV pre-S.
Phosphorylation at serine 118 results in altered migration in SDS-PAGE
(Fig. 3). As noted by others, this was not the case for several
additional, minor pre-S phosphorylation sites, which were detectable
only after 33P labeling of mutants and two-dimensional gel
electrophoresis (20). Therefore, serine 118 appears to be
situated at a structurally distinguished position in the DHBV pre-S
sequence. A high density of proline residues, as well as a substantial
variability (including amino acid insertions and deletions in closely
related avian viruses [Fig. 8] and,
particularly, a 7-amino-acid insertion in the more distantly related
heron hepatitis B virus [52]), is characteristic of
the amino acid sequence surrounding this site in the L proteins of
avian hepadnaviruses. This suggests that serine 118 may be part of a
hinge element separating the receptor-binding domain (mapped to pre-S
amino acids 30 to 115 [57]) from the C-terminal part
of DHBV pre-S, for which mutational analysis and peptide scanning data
indicate that it is required for interaction with the cytosolic
nucleocapsid during morphogenesis (22, 33). Thus,
phosphorylation at serine 118 may conceivably trigger structural alterations which directly or indirectly modulate structural and nonstructural pre-S functions (such as transactivation), possibly through homomeric or heteromeric pre-S interactions, as is known to be
the case in other regulatory proteins.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 8.
DHBV L phosphorylation occurs at a MAP kinase
recognition motif which is conserved in the pre-S domains of avian and
mammalian hepadnaviruses. The motif is boxed. Phosphorylation target
sites within the PX(S/T)P motif are indicated in boldface. The
experimentally determined phosphorylation site of DHBV L is marked with
an asterisk. RGHV, Ross's goose hepatitis B virus (38);
SGHV, snow goose hepatitis B virus (59); GSHV, ground
squirrel hepatitis B virus (50); WHV, woodchuck hepatitis B
virus (16). The HBV sequence shown is derived from subtype
ayw (17). The MAP kinase motif is not conserved in the
homologous sequence of heron hepatitis B virus, another avian
hepadnavirus (52).
|
|
Of particular interest is the novel finding that L phosphorylation, and
therefore most likely also L-mediated transactivation, is modulated in
response to intra- or extracellular signals. The levels of the
phosphorylated species, while barely detectable under physiological
conditions in the liver, increased rapidly when the hepatocytes were
liberated during liver perfusion, and L phosphorylation was further
enhanced by a variety of specific stimuli (Fig. 5). Several lines of
evidence indicate that this modulation of L phosphorylation, and of
phospho-L-mediated signaling, involves MAP kinases of the ERK-type
(7, 35): (i) the phosphorylation site, serine 118, is part
of the ERK consensus target sequence PX(S/T)P (Fig. 8); (ii)
recombinant ERK2 phosphorylated wild-type L protein but not the mutant
S118A in vitro; (iii) L protein phosphorylation was inhibited in
transfected cells by coexpression of CL100, a phosphatase specifically
inactivating MAP kinases; (iv) the induction pattern observed for
phospho-L (p36) in DHBV-infected PDHs matched that of ERK-type MAP
kinases with respect to the positive response to proliferative stimuli
such as treatment with TPA or liberation of the hepatocytes from the
liver tissue; and (v) induction of L phosphorylation was closely
correlated with ERK activation in DHBV-infected PDHs (Fig. 5B).
Although predominantly in the cell nucleus, activated ERK protein
kinases are initially cytosolic (10), and therefore, even
membrane-associated pre-S should be accessible for this type of kinase.
Our data thus support a model in which L-mediated modulation of gene
expression varies in response to specific extracellular stimuli through
serine 118 phosphorylation by ERK-type MAP kinases.
The enhancement of gene expression observed in cotransfection with an
AP-1-driven reporter construct (up to 10-fold induction) was in a range
similar to that observed in analogous experiments characterizing the
transactivation activity of the HBV L protein (24) or of the
HBV X protein (46). It is thus conceivable that DHBV L
initiates signaling via the Ras-Raf-MAP kinase cascade from a
cytoplasmic location, as has been proposed for activation of gene
expression by HBV X and HBV L (see, e.g., references
13 and 24). Two other mechanisms
also discussed for the HBV transactivators appear to be less likely:
nuclear localization and direct promoter activation, as proposed for
the X protein (9, 13), would require the release of the L
transactivator protein from its membrane-anchored state. Alternatively,
a mechanism involving oxidative stress due to accumulation of
overexpressed viral membrane proteins in the endoplasmic reticulum of
transfected cells, as postulated to explain the transactivation
potential of truncated HBV envelope proteins and of the influenza virus
hemagglutinin (36, 40), is highly unlikely for DHBV pre-S in
view of our finding that transactivation was abolished by a single
amino acid exchange without L protein expression levels being affected.
In the context of this discussion, it may be recalled that there is,
despite extensive efforts, still no conclusive model reconciling rather
conflicting data on the mechanisms involved in HBV X transactivation
and on the primary targets of this apparently pleiotropically acting
protein. In addition to experimental difficulties, this probably
relates to the fact that research on HBV X (as well as HBV L) function
has so far been mainly aimed at finding a potential link to
HBV-associated carcinogenesis, while no major studies have been
undertaken to elucidate the role by which the HBV transactivators contribute to the establishment and/or maintenance of infection by
mammalian hepadnaviruses. As exemplified by this study, DHBV offers
better opportunities to investigate hepadnavirus transactivator function also in infection experiments, and furthermore, it encodes, to
our present knowledge, only a single transactivator protein. Information gained from this avian system may therefore also contribute to a better understanding of analogous mechanisms in HBV: for example,
it will be of interest to determine whether the HBV L protein is
phosphorylated in the pre-S domain at a MAP kinase recognition motif
analogous to the one analyzed here for DHBV and conserved between
mammalian hepadnaviruses; this predicted target site (serine 98 in the
HBV ayw subtype [Fig. 8]), however, lies outside the HBV pre-S region
determined previously to specify transactivation (essentially the
pre-S2 subdomain starting at amino acid residue 109 [25]).
L phosphorylation and the associated transactivation function are
apparently not essential for the basic viral life cycle. Cell culture
and in vivo experiments showed no significant influence on virus
replication of the mutation inactivating the phosphorylation site
(S118A) (Fig. 7), in agreement with data from two other studies identifying this site by mutational analysis (4, 20).
Furthermore, no revertants to the wild-type pre-S sequence were
detected upon serial passage in test animals. Likewise, no significant
effects of the S118D mutation on virus replication were observed,
except for a selective disadvantage of S118D-DHBV in direct competition with wild-type virus in mixed infections in vivo (47). This lack of major effects with respect to virus replication is, however, in
contrast to the appearance of a distinct pathogenic phenotype with
severe growth retardation and pathologic liver histology in
S118D-DHBV-infected animals (47). Given the low level of L
phosphorylation in the steady-state liver, such a change to a
pathogenic phenotype caused by a mutation mimicking constitutive phosphorylation supports the hypothesis that L phosphorylation and
transactivation provide a subtle regulatory device mediating intracellular host-virus cross talk in response to an unbalanced state
of the cell.
 |
ACKNOWLEDGMENTS |
We thank Bärbel Glass for preparation of PDHs and virus
stocks, Armin Bosserhoff and Rainer Frank for advice on peptide
analysis, Hans Will for providing unpublished sequence information from new isolates of avian hepadnaviruses, Elizabeth Grgacic and David Anderson for the exchange of unpublished data, Karin Coutinho for
expert editorial assistance, and Elisabeth Grgacic for critically reading the manuscript during revision.
This work was supported by a grant from the Deutsche
Forschungsgemeinschaft (SFB 229) and by Fonds der Chemischen Industrie.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Zentrum
für Molekulare Biologie Heidelberg, Im Neuenheimer Feld 282, D-69124 Heidelberg, Germany. Phone: 49 6221 54 68 85. Fax: 49 6221 54 58 93. E-mail: hshd{at}zmbh.uni-heidelberg.de.
 |
REFERENCES |
| 1.
|
Alessi, D. R.,
Y. Saito,
D. G. Campbell,
P. Cohen,
G. Sithanandam,
U. Rapp,
A. Ashworth,
C. J. Marshall, and S. Cowley.
1994.
Identification of the sites in MAP kinase kinase-phosphorylated by p74raf-1.
EMBO J.
13:1610-1619[Medline].
|
| 2.
|
Alessi, D. R.,
C. Smythe, and S. M. Keyse.
1993.
The human CL100 gene encodes a Tyr/Thr-protein phosphatase which potently and specifically inactivates MAP kinase and suppresses its activation by oncogenic ras in Xenopus oocyte extracts.
Oncogene
8:2015-2020[Medline].
|
| 3.
|
Annan, R. S., and S. A. Carr.
1996.
Phosphopeptide analysis by matrix-assisted laser desorption time-of-flight mass spectrometry.
Anal. Chem.
68:3413-3421[Medline].
|
| 4.
|
Borel, C.,
C. Sunyach,
O. Hantz,
C. Trepo, and A. Kay.
1998.
Phosphorylation of DHBV pre-S: identification of the major site of phosphorylation and effects of mutations on the virus life cycle.
Virology
242:90-98[Medline].
|
| 5.
|
Boyle, W. J.,
P. van der Geer, and T. Hunter.
1991.
Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates.
Methods Enzymol.
201:110-149[Medline].
|
| 6.
|
Bruss, V.
1997.
A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation.
J. Virol.
71:9350-9357[Abstract].
|
| 7.
|
Cano, E., and L. C. Mahadevan.
1995.
Parallel signal processing among mammalian MAPKs.
Trends Biochem. Sci.
20:117-122[Medline].
|
| 8.
|
Cavanaugh, V. J.,
L. G. Guidotti, and V. C. Chisari.
1998.
Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infection in transgenic mice.
J. Virol.
72:2630-2637[Abstract/Free Full Text].
|
| 9.
|
Cheong, J. H.,
M. Yi,
Y. Lin, and S. Murakami.
1995.
Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation.
EMBO J.
14:143-150[Medline].
|
| 10.
|
Cohen, P.
1997.
The search for physiological substrates of MAP and SAP kinases in mammalian cells.
Trends Cell Biol.
7:353-361.
|
| 11.
|
Condreay, L. D.,
C. E. Aldrich,
L. Coates,
W. S. Mason, and T. T. Wu.
1990.
Efficient duck hepatitis B virus production by an avian liver tumor cell line.
J. Virol.
64:3249-3258[Abstract/Free Full Text].
|
| 12.
|
Davis, R. J.
1993.
The mitogen-activated protein kinase signal transduction pathway.
J. Biol. Chem.
268:14553-14556[Free Full Text].
|
| 13.
|
Doria, M.,
N. Klein,
R. Lucito, and R. J. Schneider.
1995.
The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors.
EMBO J.
14:4747-4757[Medline].
|
| 14.
|
Faktor, O., and Y. Shaul.
1990.
The identification of hepatitis B virus X gene responsive elements reveals functional similarity of X and HTLV-I tax.
Oncogene
5:867-872[Medline].
|
| 15.
|
Fernholz, D.,
G. Wildner, and H. Will.
1993.
Minor envelope proteins of duck hepatitis B virus are initiated at internal pre-S AUG codons but are not essential for infectivity.
Virology
197:64-73[Medline].
|
| 16.
|
Galibert, F.,
T. N. Chen, and E. Mandart.
1982.
Nucleotide sequence of a cloned woodchuck hepatitis virus genome: comparison with the hepatitis B virus sequence.
J. Virol.
41:51-65[Abstract/Free Full Text].
|
| 17.
|
Galibert, F.,
E. Mandart,
F. Fitoussi,
P. Tiollais, and P. Charnay.
1979.
Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli.
Nature
281:646-650[Medline].
|
| 18.
|
Ganem, D.
1996.
Hepadnaviridae and their replication, p. 2703-2737.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Field's virology. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 19.
|
Grgacic, E. V., and D. A. Anderson.
1994.
The large surface protein of duck hepatitis B virus is phosphorylated in the pre-S domain.
J. Virol.
68:7344-7350[Abstract/Free Full Text].
|
| 20.
|
Grgacic, E. V. L.,
B. Lin,
E. V. Gazina,
M. J. Snooks, and D. A. Anderson.
1998.
Normal phosphorylation of duck hepatitis B virus L protein is dispensable for infectivity.
J. Gen. Virol.
79:2743-2751[Abstract].
|
| 21.
|
Guidotti, L. G.,
B. Matzke,
H. Schaller, and F. V. Chisari.
1995.
High-level hepatitis B virus replication in transgenic mice.
J. Virol.
69:6158-6169[Abstract].
|
| 22.
|
Hild, M.
1997.
Zelluläre Funktionen während der frühen und späten Schritte im Infektionszyklus des Enten Hepatitis B Virus. Ph.D. thesis.
University of Heidelberg, Heidelberg, Germany.
|
| 23.
|
Hild, M.,
O. Weber, and H. Schaller.
1998.
Glucagon treatment interferes with an early step of duck hepatitis B infection.
J. Virol.
72:2600-2606[Abstract/Free Full Text].
|
| 24.
|
Hildt, E.,
G. Saher,
V. Bruss, and P. H. Hofschneider.
1996.
The hepatitis B virus large surface protein (LHBs) is a transcriptional activator.
Virology
225:235-239[Medline].
|
| 25.
|
Hildt, E.,
S. Urban, and P. H. Hofschneider.
1995.
Characterization of essential domains for the functionality of the MHBst transcriptional activator and identification of a minimal MHBst activator.
Oncogene
11:2055-2066[Medline].
|
| 26.
|
Kekule, A. S.,
U. Lauer,
M. Meyer,
W. H. Caselmann,
P. H. Hofschneider, and R. Koshy.
1990.
The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator.
Nature
343:457-461[Medline].
|
| 27.
|
Kekule, A. S.,
U. Lauer,
L. Weiss,
B. Luber, and P. H. Hofschneider.
1993.
Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway.
Nature
361:742-745[Medline].
|
| 28.
|
Kemp, B. E., and R. B. Pearson.
1990.
Protein kinase recognition sequence motifs.
Trends Biochem. Sci.
15:342-346[Medline].
|
| 29.
|
Keyse, S. M.
1995.
An emerging family of dual specificity MAP kinase phosphatases.
Biochim. Biophys. Acta.
1265:152-160[Medline].
|
| 30.
|
Klingmüller, U., and H. Schaller.
1993.
Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor.
J. Virol.
67:7414-7422[Abstract/Free Full Text].
|
| 31.
|
Krishna, R. G., and F. Wold.
1993.
Post-translational modifications of proteins, p. 167-172.
In
K. Imahori, and F. Sakiyma (ed.), Methods in protein sequence analysis. Plenum Press, New York, N.Y.
|
| 32.
|
Kyriakis, J. M., and J. Avruch.
1996.
Sounding the alarm: protein kinase cascades activated by stress and inflammation.
J. Biol. Chem.
271:24313-24316[Free Full Text].
|
| 33.
|
Lenhoff, R. J., and J. Summers.
1994.
Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus.
J. Virol.
68:4565-4571[Abstract/Free Full Text].
|
| 34.
|
Mandart, E.,
A. Kay, and F. Galibert.
1984.
Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences.
J. Virol.
49:782-7892[Abstract/Free Full Text].
|
| 35.
|
Marais, R., and C. J. Marshall.
1996.
Control of the ERK MAP kinase cascade by Ras and Raf.
Cancer Surv.
27:101-125[Medline].
|
| 36.
|
Meyer, M.,
W. H. Caselmann,
V. Schluter,
R. Schreck,
P. H. Hofschneider, and P. A. Baeuerle.
1992.
Hepatitis B virus transactivator MHBst: activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization.
EMBO J.
11:2991-3001[Medline].
|
| 37.
|
Nassal, M., and H. Schaller.
1996.
Hepatitis B virus replication an update.
J. Viral Hep.
3:217-226.
|
| 38.
| Newbold, J. E., et al. GenBank accession
number M95589.
|
| 39.
|
Obert, S.,
B. Zachmann Brand,
E. Deindl,
W. Tucker,
R. Bartenschlager, and H. Schaller.
1996.
A spliced hepadnavirus RNA that is essential for virus replication.
EMBO J.
15:2565-2574[Medline].
|
| 40.
|
Pahl, H. L., and P. A. Baeuerle.
1995.
Expression of influenza virus hemagglutinin activates transcription factor NF-kappa B.
J. Virol.
69:1480-1484[Abstract].
|
| 41.
| Protzer, U., U. Klöcker, and H. Schaller.
Unpublished data.
|
| 42.
|
Pugh, J. C.,
J. J. Sninsky,
J. W. Summers, and E. Schaeffer.
1987.
Characterization of a pre-S polypeptide on the surfaces of infectious avian hepadnavirus particles.
J. Virol.
61:1384-1390[Abstract/Free Full Text].
|
| 43.
|
Radler-Pohl, A.,
C. Sachsenmaier,
S. Gebel,
H. P. Auer,
J. T. Bruder,
U. Rapp,
P. Angel,
H. J. Rahmsdorf, and P. Herrlich.
1993.
UV-induced activation of AP-1 involves obligatory extranuclear steps including Raf-1 kinase.
EMBO J.
12:1005-1012[Medline].
|
| 44.
|
Radziwill, G.,
W. Tucker, and H. Schaller.
1990.
Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity.
J. Virol.
64:613-620[Abstract/Free Full Text].
|
| 45.
|
Rigg, R. J., and H. S. Challer.
1992.
Duck hepatitis B virus infection of hepatocytes is not dependent on low pH.
J. Virol.
66:2829-2836[Abstract/Free Full Text].
|
| 46.
|
Rossner, M. T.
1992.
Hepatitis B virus X-gene product: a promiscuous transcriptional activator.
J. Med. Virol.
36:101-117[Medline].
|
| 47.
| Rothmann, K., W. J. Hofmann, B. Glass, and H. Schaller. 1998. Unpublished data.
|
| 48.
|
Schagger, H., and G. von Jagow.
1987.
Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.
Anal. Biochem.
166:368-379[Medline].
|
| 49.
|
Schlicht, H. J.,
C. Kuhn,
B. Guhr,
R. J. Mattaliano, and H. Schaller.
1987.
Biochemical and immunological characterization of the duck hepatitis B virus envelope proteins.
J. Virol.
61:2280-2285[Abstract/Free Full Text].
|
| 50.
|
Seeger, C.,
D. Ganem, and H. E. Varmus.
1984.
Nucleotide sequence of an infectious molecularly cloned genome of ground squirrel hepatitis virus.
J. Virol.
51:367-375[Abstract/Free Full Text].
|
| 51.
|
Songyang, Z.,
K. P. Lu,
Y. T. Kwon,
L. H. Tsai,
O. Filhol,
C. Cochet,
D. A. Brickey,
T. R. Soderling,
C. Bartleson,
D. J. Graves,
A. J. DeMaggio,
M. F. Hoekstra,
J. Blenis,
T. Hutner, and L. C. Cantley.
1996.
A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1.
Mol. Cell Biol.
16:6486-6493[Abstract].
|
| 52.
|
Sprengel, R.,
E. F. Kaleta, and H. Will.
1988.
Isolation and characterization of a hepatitis B virus endemic in herons.
J. Virol.
62:3832-3839[Abstract/Free Full Text].
|
| 53.
|
Sprengel, R.,
C. Kuhn,
H. Will, and H. Schaller.
1985.
Comparative sequence analysis of duck and human hepatitis B virus genomes.
J. Med Virol.
15:323-333[Medline].
|
| 54.
|
Summers, J.,
P. M. Smith,
M. J. Huang, and M. S. Yu.
1991.
Morphogenetic and regulatory effects of mutations in the envelope proteins of an avian hepadnavirus.
J. Virol.
65:1310-1317[Abstract/Free Full Text].
|
| 55.
|
Swameye, I., and H. Schaller.
1997.
Dual topology of the large envelope protein of duck hepatitis B virus: determinants preventing pre-S translocation and glycosylation.
J. Virol.
71:9434-9441[Abstract].
|
| 56.
|
Tuttleman, J. S.,
C. Pourcel, and J. Summers.
1986.
Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells.
Cell
47:451-460[Medline].
|
| 57.
|
Urban, S.,
K. M. Breiner,
F. Fehler,
U. Klingmüller, and H. Schaller.
1998.
Avian hepatitis B virus infection is initiated by the interaction of a distinct pre-S subdomain with the cellular receptor gp180.
J. Virol.
72:8089-8097[Abstract/Free Full Text].
|
| 58.
|
Wei, Y., and D. Ganem.
1998.
Activation of heterologous gene expression by the large isoform of the hepatitis delta antigen.
J. Virol.
72:2089-2096[Abstract/Free Full Text].
|
| 59.
| Will, H., H. J. Netter, and S. F. Chang.
Personal communication.
|
| 60.
|
Yaginuma, K.,
Y. Shirakata,
M. Kobayashi, and K. Koike.
1987.
Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA.
Proc. Natl. Acad. Sci. USA
84:2678-2682[Abstract/Free Full Text].
|
| 61.
|
Zoulim, F.,
J. Saputelli, and C. Seeger.
1994.
Woodchuck hepatitis virus X protein is required for viral infection in vivo.
J. Virol.
68:2026-2030[Abstract/Free Full Text].
|
Journal of Virology, December 1998, p. 10138-10147, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Maenz, C., Chang, S.-F., Iwanski, A., Bruns, M.
(2007). Entry of Duck Hepatitis B Virus into Primary Duck Liver and Kidney Cells after Discovery of a Fusogenic Region within the Large Surface Protein. J. Virol.
81: 5014-5023
[Abstract]
[Full Text]
-
Shin, Y.-K., Liu, Q., Tikoo, S. K., Babiuk, L. A., Zhou, Y.
(2007). Effect of the phosphatidylinositol 3-kinase/Akt pathway on influenza A virus propagation. J. Gen. Virol.
88: 942-950
[Abstract]
[Full Text]
-
Grgacic, E. V. L., Anderson, D. A.
(2005). St, a Truncated Envelope Protein Derived from the S Protein of Duck Hepatitis B Virus, Acts as a Chaperone for the Folding of the Large Envelope Protein. J. Virol.
79: 5346-5352
[Abstract]
[Full Text]
-
Esfandiarei, M., Luo, H., Yanagawa, B., Suarez, A., Dabiri, D., Zhang, J., McManus, B. M.
(2004). Protein Kinase B/Akt Regulates Coxsackievirus B3 Replication through a Mechanism Which Is Not Caspase Dependent. J. Virol.
78: 4289-4298
[Abstract]
[Full Text]
-
Urban, S., Gripon, P.
(2002). Inhibition of Duck Hepatitis B Virus Infection by a Myristoylated Pre-S Peptide of the Large Viral Surface Protein. J. Virol.
76: 1986-1990
[Abstract]
[Full Text]
-
Mu, J.-J., Chen, D.-S., Chen, P.-J.
(2001). The Conserved Serine 177 in the Delta Antigen of Hepatitis Delta Virus Is One Putative Phosphorylation Site and Is Required for Efficient Viral RNA Replication. J. Virol.
75: 9087-9095
[Abstract]
[Full Text]
-
Clayton, R. F., Owsianka, A., Patel, A. H.
(2001). Evidence for structural differences in the S domain of L in comparison with S protein of hepatitis B virus. J. Gen. Virol.
82: 1533-1541
[Abstract]
[Full Text]
-
Yao, E., Gong, Y., Chen, N., Tavis, J. E.
(2000). The Majority of Duck Hepatitis B Virus Reverse Transcriptase in Cells Is Nonencapsidated and Is Bound to a Cytoplasmic Structure. J. Virol.
74: 8648-8657
[Abstract]
[Full Text]
-
Klöcker, U., Schultz, U., Schaller, H., Protzer, U.
(2000). Endotoxin Stimulates Liver Macrophages To Release Mediators That Inhibit an Early Step in Hepadnavirus Replication. J. Virol.
74: 5525-5533
[Abstract]
[Full Text]
-
Grgacic, E. V. L., Schaller, H.
(2000). A Metastable Form of the Large Envelope Protein of Duck Hepatitis B Virus: Low-pH Release Results in a Transition to a Hydrophobic, Potentially Fusogenic Conformation. J. Virol.
74: 5116-5122
[Abstract]
[Full Text]
-
Grgacic, E. V. L., Kuhn, C., Schaller, H.
(2000). Hepadnavirus Envelope Topology: Insertion of a Loop Region in the Membrane and Role of S in L Protein Translocation. J. Virol.
74: 2455-2458
[Abstract]
[Full Text]
-
Mu, J.-J., Wu, H.-L., Chiang, B.-L., Chang, R.-P., Chen, D.-S., Chen, P.-J.
(1999). Characterization of the Phosphorylated Forms and the Phosphorylated Residues of Hepatitis Delta Virus Delta Antigens. J. Virol.
73: 10540-10545
[Abstract]
[Full Text]
-
Schmitt, S., Glebe, D., Alving, K., Tolle, T. K., Linder, M., Geyer, H., Linder, D., Peter-Katalinic, J., Gerlich, W. H., Geyer, R.
(1999). Analysis of the Pre-S2 N- and O-Linked Glycans of the M Surface Protein from Human Hepatitis B Virus. J. Biol. Chem.
274: 11945-11957
[Abstract]
[Full Text]